Fenofibrate is generally prescribed as an adjunct to diet when addressing conditions characterized by periods of heightened symptoms related to systemic imbalance. Its main indications are the treatment of primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. The core function of fenofibrate is commonly used to help with reducing elevated levels of key lipids, including LDL-C and Triglycerides, while contributing to increasing HDL-C. This approach supports general well-being during symptomatic phases by assisting with maintaining functional stability of lipid levels. For individuals with severe hypertriglyceridemia, the medication is applied in addressing symptoms linked to organ-specific functional stress. This type of support is often used during phases when symptoms become more noticeable. “It provides support that helps ease the overall symptom burden when symptoms become more noticeable.”

---

Quick Fact Block

Quick Fact: Relief for Symptoms related to systemic imbalance

Eligibility for Fenofibrate

Fenofibrate is an anti-lipid agent approved for adult patients with diagnosed primary hypercholesterolemia, mixed dyslipidemia, or severe hypertriglyceridemia. Its use is defined by specific restrictions related to organ function and patient status, which are outlined in official regulatory documents.

---

Populations for whom use is Contraindicated (Must Not Use)

Fenofibrate is formally contraindicated in patients with:

• Severe renal impairment, including those receiving dialysis.
• Active liver disease, including primary biliary cirrhosis or unexplained persistent liver function abnormalities.
• Pre-existing gallbladder disease.
• Known hypersensitivity to fenofibrate or fenofibric acid.
• Nursing mothers (breastfeeding women).

---

Restricted and Age-Related Eligibility

Classification	Rule (Official Regulatory Statement)
Pediatric Use	Not recommended; safety and efficacy in children under 18 years are not established.
Renal Impairment	Dose reduction is required for patients with mild to moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m^2).
Geriatric Use	Dose selection should be determined based on renal function due to age-related decline.
Pregnancy Status	Use is permitted only if the potential benefit justifies the potential risk to the fetus.

---

Regulatory documentation establishes strict boundaries for fenofibrate use, primarily excluding individuals with severe organ dysfunction to prevent drug accumulation and mitigate risks to conditions like gallbladder disease. The rules classify the pediatric population as non-eligible due to insufficient data, while requiring mandatory adjustments for those with moderate kidney limitations.

Interactions with other medicines and products

Official regulatory information for Fenofibrate details interaction patterns primarily focused on managing additive toxicity and preventing alterations in drug exposure. Co-administration with other fibrates, such as Gemfibrozil, is explicitly restricted due to a severe, additive risk of muscle toxicity, including rhabdomyolysis. The combined use of Fenofibrate with HMG-CoA Reductase Inhibitors (Statins) should also generally be avoided for the same reason, with regulatory caution mandated if benefits are deemed to outweigh the increased risk.

Documented Exposure and Administration Constraints

Fenofibrate potentiates the anticoagulant effect of Coumarin-type oral anticoagulants, necessitating mandatory close monitoring of Prothrombin Time/INR and subsequent dosage adjustment of the anticoagulant upon initiation. Co-administration with Immunosuppressants (e.g., Cyclosporine) is associated with a risk of reversible renal function deterioration. For adequate absorption, Fenofibrate must be taken with food. Furthermore, administration requires mandatory time separation from Bile Acid Binding Resins: Fenofibrate must be taken at least 1 hour before or 4 to 6 hours after the resin to prevent physical drug binding.

Фенόфибрат (Fenofibrate) is a pro-drug whose mechanism of action is mediated by its active metabolite, fenofibric acid. This metabolite acts as an agonist (activator) of the nuclear receptor Peroxisome Proliferator-Activated Receptor alpha ( PPARalpha), which is expressed primarily in the liver.

Activation of PPARalpha triggers the transcription of genes responsible for lipid metabolism. This cascade results in two primary physiological modulations. First, it increases the expression of enzymes that promote the beta-oxidation of fatty acids in the liver. This heightened hepatic catabolism reduces the pool of free fatty acids available for the synthesis and subsequent secretion of very low-density lipoprotein (VLDL) particles, leading to reduced circulating triglyceride-rich particles. Second, it modifies the expression of several apolipoproteins (such as ApoA-I and ApoC-III), which alters the catabolism and composition of lipoprotein particles, resulting in altered lipoprotein kinetics and modification of the relative distribution of lipid particles across the systemic circulation.

How to Use Fenofibrate

Fenofibrate is designed for oral administration as a long-term treatment adjunct to dietary management of lipid disorders. The medicine is taken once daily.

Administration and Timing

All fenofibrate tablets and capsules must be swallowed whole and should not be split, crushed, dissolved, or chewed to maintain the intended release characteristics. The instruction for taking the drug in relation to meals is not uniform across all products; some formulations must be taken with food for proper absorption, while others may be taken regardless of meals. When co-administered with a bile acid binding resin, fenofibrate must be administered at least 1 hour before or 4 to 6 hours after the resin to avoid interference with its absorption.

If a dose is missed, treatment should be resumed with the next regularly scheduled dose; a double dose must not be taken to compensate.

Dosage Patterns and Adjustments

Standard adult regimens for hyperlipidemia and mixed dyslipidemia typically involve a once-daily dose equivalent to 145 mg or 160 mg, depending on the specific product formulation. For severe hypertriglyceridemia, a lower dose may be initiated and adjusted based on the patient's lipid response.

Dosage adjustments are determined by repeated lipid level assessments, generally conducted at intervals of 4 to 8 weeks after treatment begins. Dosing rules are modified for specific populations: for geriatric patients and those with mild to moderate renal impairment (eGFR 30 to < 60 mL/min), a reduced starting dose (e.g., 40 mg or 48 mg) is mandatory. Use in pediatric patients under 18 years is generally not recommended as safety and efficacy data are not established. If an adequate therapeutic response is not observed after two months of treatment at the maximum recommended dose, the drug is typically withdrawn.

Research evidence / Overview of Studies for Фенофибрат

---

1. Evidence for use in Severe Hypertriglyceridemia

Research on Fenofibrate was studied for its application in research exploring very high levels of triglycerides in the blood. Studies, including Randomized Controlled Trials (RCTs), primarily examined the change in triglyceride and other lipid levels in adults with severely elevated baseline levels. The findings described patterns of shifts in these biomarkers. Research also examined the association between use of the medicine and risk profiles for Pancreatitis. However, the existing research is limited in terms of long-term follow-up specifically focused on tracking the risk of clinical events over many years.

---

2. Evidence for use in Mixed Dyslipidemia and Primary Hypercholesterolemia

Fenofibrate was studied in large-scale trials and meta-analyses to explore its application in research exploring combined lipid disorders and high LDL-C. These efforts explored how the medicine influenced the entire lipid panel and were studied for association with major cardiovascular events. Findings were mixed regarding the incidence of cardiovascular events when compared to standard therapy alone in the general study population. Uncertainty remains low regarding whether the medicine shows patterns of association with event reduction when used on top of other established therapies.

---

3. Research Gaps and Limitations

The evidence base includes extended-duration trials to assess the durability of observed patterns. However, the interpretation of long-term clinical outcomes can be complex, and effects are not fully established. Studies have explored Fenofibrate in co-existing conditions like Type 2 Diabetes and in the elderly. Data for certain groups remain insufficient, including long-term outcomes for patients with pre-existing kidney issues, and comparative evidence for children is lacking. The research results apply only to the populations studied and do not determine whether an individual will respond similarly.

Key Studies & References Fenofibrate - StatPearls - NCBI Bookshelf (Review on use in geriatrics, hypertriglyceridemia, and adverse effects)

Common questions about Фенофибрат (FAQ)

---

Q: What is the main difference between Fenofibrate and statins, if they both affect lipids?

The primary difference lies in their specific mechanism of action and their main lipid targets. Official product information indicates Fenofibrate activates a receptor called PPAR-alpha, and is primarily associated with lowering triglycerides and raising 'good' HDL cholesterol. In contrast, statins work differently by inhibiting an enzyme that controls cholesterol production, primarily to reduce 'bad' LDL cholesterol.

---

Q: Does Fenofibrate help lower 'bad' cholesterol (LDL-C)?

Official product information indicates that Fenofibrate administration results in moderate reductions in 'bad' cholesterol, which is known as LDL-C. While its main purpose is managing triglycerides and HDL, it also influences LDL levels as part of its effect on the overall lipid profile.

---

Q: Why do doctors sometimes prescribe Fenofibrate to diabetics?

Official product information notes that Fenofibrate has been studied in individuals with Type 2 Diabetes Mellitus. Clinical studies confirm that the medicine has been thoroughly examined for its use and effects in this specific patient group, and regulatory documents include details relevant to this population.

---

Q: What does 'Fenofibrate is prescribed to reduce the risk of pancreatitis' mean?

This medication is officially used to manage severe hypertriglyceridemia, which is a condition involving extremely high levels of blood fats. Severe hypertriglyceridemia itself is an established risk factor for developing pancreatitis (inflammation of the pancreas). By addressing this underlying high-risk condition, use of Fenofibrate is associated with a reduction of that specific risk.

---

Q: How do I know Fenofibrate is working?

The effectiveness of Fenofibrate is typically assessed by a healthcare provider using laboratory tests. Official monitoring guidelines state that the drug's activity is determined by the periodic assessment of blood fat levels, specifically the changes in triglycerides and 'good' HDL cholesterol. These blood tests are typically performed several weeks after starting treatment.

---

Q: What is 'hyperlipidemia' and how does Fenofibrate treat it?

Hyperlipidemia is a medical term for lipid disorders, meaning you have high or unbalanced levels of fats in your blood. Fenofibrate is indicated for the treatment of high triglycerides (hypertriglyceridaemia) and mixed dyslipidemia, which is a combination of lipid abnormalities. The medicine is indicated for use as an adjunct to a controlled diet for managing these lipid imbalances.

---

Q: What are the most common reasons people stop taking Fenofibrate?

Reports from clinical trials indicate that the most frequent adverse reactions associated with discontinuation include gastrointestinal issues, such as abdominal pain. Also, abnormal changes in liver function tests, which are checked via blood work, are another common reason cited for treatment discontinuation.

---

Q: Are there serious risks when combining Fenofibrate and alcohol?

Official regulatory warnings state that caution should be exercised regarding alcohol consumption while taking this medication. Regulatory information indicates that drinking large quantities of alcohol may increase the risk of Fenofibrate causing liver problems, as both substances can affect liver function.

---

Q: Why does the leaflet say it shouldn't be used with photoallergy?

According to official regulatory documents, Fenofibrate is formally contraindicated, meaning it should not be used, if a patient has a known history of photoallergy or phototoxic reactions. This warning applies to severe skin reactions experienced during previous treatment with similar medicines (fibrates) or the drug ketoprofen.

---

Q: How does Fenofibrate interact with oral contraceptives?

Official information indicates that Fenofibrate has the potential to interact with estrogens, which are the hormones contained in some oral contraceptives. Because of this potential for interaction, regulatory information suggests that the use of hormone-based contraceptive medicines should be discussed with a healthcare provider.

---

Q: Can I take Fenofibrate if I'm already taking thyroid medication?

Official safety warnings note that hypothyroidism, which is an underactive thyroid gland, can increase the risk of developing muscle problems (myopathy) while taking Fenofibrate. Regulatory information suggests that the stability of the thyroid condition may need to be assessed and monitored before and during treatment.

---

Q: Can Fenofibrate affect blood sugar levels?

Fenofibrate can affect the metabolism of certain anti-diabetic medicines, such as those in the sulfonylurea class. When taken together, this drug interaction could potentially change a patient’s blood sugar levels. This interaction may necessitate monitoring of blood sugar levels.

---

Q: Why does Fenofibrate require caution when taken with certain antiviral drugs?

The need for caution arises because Fenofibrate has been studied for its potential pharmacokinetic interactions with certain antiviral drugs, specifically some HIV protease inhibitors. These interactions can alter how the body processes the medication, and regulatory information notes that monitoring or dosage adjustments may be required.

How to Store and Dispose of Fenofibrate

Fenofibrate must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. To maintain stability, the medication must be protected from excess heat and moisture.

Packaging and Safety

The product must remain in its original container, which should be kept tightly closed. A mandatory safety constraint requires storing the medicine out of the sight and reach of children in a secured location.

Disposal

Unused or expired Fenofibrate should be disposed of in accordance with local regulatory requirements for pharmaceutical waste. Disposal should not occur via household trash, wastewater, or drains.